(4-Methyl-12-phenyl-13-oxa-3,6-diazatricyclo[7.4.0.02,6]trideca-1(9),2,4,7-tetraen-5-yl)methanol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡喃吡啶类
• 英文名称: (4-Methyl-12-phenyl-13-oxa-3,6-diazatricyclo[7.4.0.02,6]trideca-1(9),2,4,7-tetraen-5-yl)methanol
• 化学式: C₁₈H₁₈N₂O₂
• 分子量: 294.3
• InChiKey: KEVZDVIKLAQVDM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  46.8
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Pharmaceutical preparation comprising an active dispersed on a matrix
  申请人：——

  公开号：US20040058896A1

  公开（公告）日：2004-03-25

  The present invention relates to the field of pharmaceutical technology and describes a novel advantageous preparation for an active ingredient. The novel preparation is suitable for producing a large number of pharmaceutical dosage forms. In the new preparation an active ingredient is present essentially uniformly dispersed in an excipient matrix composed of one or more excipients selected from the group of fatty alcohol, triglyceride, partial glyceride and fatty acid ester.

  本发明涉及制药技术领域，描述了一种新的有利的活性成分制备方法。这种新的制备方法适用于生产大量的药物剂型。在这种新的制备方法中，活性成分基本上均匀地分散在由脂肪醇、甘油三酯、部分甘油酯和脂肪酸酯等多种赋形剂中选择的一种或多种赋形剂组成的赋形剂基质中。
• Pharmaceutical formulatins useful for inhibiting acid secretion and methods for making and using them
  申请人：Hall Warren

  公开号：US20050037070A1

  公开（公告）日：2005-02-17

  In one general aspect of the present invention, pharmaceutical formulations comprising both a proton pump inhibitor microencapsulated with a material that enhances the shelf-life of the pharmaceutical composition and one or more antacid are described. In another general aspect of the present invention, pharmaceutical formulations comprising both a proton pump inhibitor microencapsulated with a taste-masking material and one or more antacid are described.

  在本发明的一般方面中，描述了包含质子泵抑制剂微胶囊化的药物配方，该微胶囊化物质增强了药物组合物的货架寿命，同时还包含一种或多种抗酸剂。在本发明的另一一般方面中，描述了包含质子泵抑制剂微胶囊化的药物配方，该微胶囊化物质具有掩味作用，并包含一种或多种抗酸剂。
• Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
  申请人：Hall Warren

  公开号：US20060204585A1

  公开（公告）日：2006-09-14

  In one general aspect of the present invention, pharmaceutical formulations comprising both a proton pump inhibitor microencapsulated or dry coated with a material that enhances the shelf-life of the pharmaceutical composition and one or more antacid are described. In another general aspect of the present invention, pharmaceutical formulations comprising both a proton pump inhibitor microencapsulated or dry coated with a taste-masking material and one or more antacid are described.

  在本发明的一般方面中，描述了含有质子泵抑制剂微囊化或干燥涂层的药物制剂，该涂层增强了药物组成物的货架寿命，并且含有一个或多个抗酸剂。在本发明的另一个一般方面中，描述了含有微囊化或干燥涂层的质子泵抑制剂和一种或多种抗酸剂的药物制剂，该涂层用于掩盖药物的味道。
• Multi-chambered apparatus comprising a dispenser head
  申请人：The Curators Of The University Of Missouri

  公开号：EP2486910A2

  公开（公告）日：2012-08-15

  The present disclosure relates to a multi-chambered apparatus comprising: a first chamber wherein one or more first pharmaceutically active agents, protective buffers or thickeners can be contained; a second chamber wherein one or more second pharmaceutically active agents, flavoring agents, sweeteners, disintegrants, additives, buffering agents, or thickeners can be contained; and a dispenser head.

  本公开涉及一种多室装置，包括 第一腔室，可容纳一种或多种第一药物活性剂、保护性缓冲剂或增稠剂； 第二腔室，可容纳一种或多种第二药用活性剂、调味剂、甜味剂、崩解剂、添加剂、缓冲剂或增稠剂；以及 分配器头。
• Compositions useful for treating gastrointestinal motility disorders
  申请人：Landau B. Steven

  公开号：US20050059704A1

  公开（公告）日：2005-03-17

  The present invention relates to method of treating a gastrointestinal motility disorder in a subject in need of treatment comprising coadministering to said subject a first amount of a compound having 5-HT 3 receptor agonist activity or a pharmaceutically acceptable salt, hydrate or solvate thereof; and a second amount of at least one gastric acid suppressing agent (e.g., a proton pump inhibitor, an H 2 receptor antagonist or a pharmaceutically acceptable salt, hydrate or solvate thereof; or an acid pump antagonist or pharmaceutically acceptable salt, hydrate or solvate thereof) wherein the first and second amounts together comprise a therapeutically effective amount. In particular, the method is for treating GERD, including nocturnal GERD. The invention further relates to a method of treating nocturnal GERD comprising administering to a subject in need thereof a therapeutically effective amount of a compound having 5-HT 3 receptor agonist activity or a pharmaceutically acceptable salt, hydrate or solvate thereof. The invention further relates to a method of increasing esophageal motility in a subject in need thereof. The method of increasing esophageal motility can be achieved by administration of a compound having 5-HT 3 receptor agonist activity or a pharmaceutically acceptable salt, hydrate or solvate thereof. The coadministration can also be used to increase esophageal motility.

  本发明涉及治疗需要治疗的受试者胃肠道运动紊乱的方法，包括向所述受试者联合施用第一种量的具有 5-HT 3 受体激动剂活性的化合物或其药学上可接受的盐、水合物或溶液；以及第二种量的至少一种胃酸抑制剂（如质子泵抑制剂、H 2 受体拮抗剂或其药学上可接受的盐、水合物或溶液；或酸泵拮抗剂或其药学上可接受的盐、水合物或溶液），其中第一和第二量共同构成治疗有效量。特别是，该方法用于治疗胃食管反流病，包括夜间胃食管反流病。本发明进一步涉及一种治疗夜间胃食管反流病的方法，该方法包括向有需要的受试者施用治疗有效量的具有 5-HT 3 受体激动剂活性的化合物或其药学上可接受的盐、水合物或溶液。本发明进一步涉及一种增加需要者食管蠕动的方法。增加食管蠕动的方法可通过给予具有 5-HT 3 受体激动剂活性的化合物或其药学上可接受的盐、水合物或溶液。联合给药也可用于增加食管运动。